Form 4: ResMed Director DelOrefice Acquires 1,073 RSUs

ResMed Director Christopher DelOrefice was granted 1,073 Restricted Stock Units, increasing his beneficial ownership to 2,423 shares.

Summary

• Christopher DelOrefice, a Director at ResMed Inc. (RMD), acquired 1,073 shares of ResMed Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on November 20, 2025.
• The RSUs were granted at a price of $0, which is typical for equity compensation.
• Following this transaction, Mr. DelOrefice beneficially owns a total of 2,423 shares of ResMed Common Stock directly.
• These RSUs are scheduled to vest in full on the earlier of November 11, 2026, or the date of the annual meeting of stockholders in the year following the grant date.

Sentiment

Score: 6

Explanation: The acquisition of Restricted Stock Units by a director is generally viewed as a neutral to slightly positive event, as it aligns management's interests with shareholders, but it is a form of compensation rather than an open market purchase.

Positives

• Director Christopher DelOrefice received an equity grant of 1,073 Restricted Stock Units, aligning his interests further with shareholders.
• The grant increases his total beneficial ownership to 2,423 shares, demonstrating continued commitment to the company.

Negatives

• No explicit negatives are reported in this Form 4 filing.

Risks

• The value of the Restricted Stock Units is subject to the future market price of ResMed Common Stock.
• Vesting of the RSUs is contingent upon Mr. DelOrefice's continued service to the company until the vesting date.

Future Outlook

The filing does not contain forward-looking statements or guidance beyond the vesting schedule of the Restricted Stock Units.

Industry Context

Equity compensation, such as Restricted Stock Units, is a common practice across various industries, including medical device and healthcare technology, to attract, retain, and incentivize directors and executives. This specific filing does not provide broader industry trends.

Comparison to Industry Standards

• The grant of Restricted Stock Units to a director is a standard form of non-cash compensation in publicly traded companies. The specific number of units granted would typically be benchmarked against peer companies in the medical technology sector, but this filing does not provide such comparative data.

Related Party Transactions

• The grant of Restricted Stock Units to Director Christopher DelOrefice constitutes a related party transaction, as it involves the company providing compensation to a member of its board.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's long-term interests with those of shareholders, potentially encouraging decisions that enhance shareholder value. However, it also represents a dilutive event upon vesting, though typically minor for individual grants.

Next Steps

• Vesting of the 1,073 Restricted Stock Units on the earlier of November 11, 2026, or the annual meeting of stockholders in the year following the grant date.

Key Dates

Keywords

RMD, ResMed, Form 4, Insider Transaction, Director, RSU, Restricted Stock Units, Equity Compensation